Appointments: Rice Goes To CVS, A New CFO At J&J And Changes at Merck & Co, Alder, Hansa, OncoMed, Modus Therapeutics, Astellas Americas And Others
Executive Summary
This week's new appointments include the move by the second former big pharma executive to a PBM in the space of a week, plus a new CFO at Johnson & Johnson, and new CEOs at Alder BioPharmaceuticals, OncoMed and Hansa Medical. Other hires were announced by Astellas Americas, Merck & Co, Valbiotis, Bicycle Therapeutics, Sorrento Therapeutics, Gritstone Oncology and Oxford BioMedica.
You may also be interested in...
From Pharma Insider To Payer: Witty To Lead United's Optum
Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.
Pipeline Watch: Six Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Three New CMOs And CFOs Among This Week's Changes
Recent moves in the industry include C-suite shuffles at PureTech Health and Traws Pharma, plus Xencor gets a new chief financial officer.